681 top medical experts on Behcet Syndrome across 48 countries and 29 U.S. states, including 510 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Behcet Syndrome: Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. synovitis; thrombophlebitis; gastrointestinal ulcerations; retinal vasculitis; and optic atrophy may occur as well.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Mouth Diseases (1,845), Vasculitis (2,306), Hereditary Autoinflammatory Diseases (2,464), Vascular Skin Diseases (2,116).
  4. Clinical Trials ClinicalTrials.gov : at least 85 including 43 Completed, 12 Recruiting
  5. Synonyms: Behcet Disease,  Behcet's Disease,  Behcet's Syndrome,  Triple-Symptom Complex


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Yazici, Yusuf   Rheumatology   ClinicalTrials.gov Google Publications
    New York University School of Medicine, New York, New York, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1994)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $5,107.13, including $5,107.13 from  Amgen Inc.
    Subjects: Thalidomide; Anti-Inflammatory Agents, Non-Steroidal; Oral Ulcer; Phosphodiesterase 4 Inhibitors; Practice Patterns, Physicians
    Categories: Drug Therapy; Therapeutic Use; Diagnosis; Physiopathology; Standards; Analogs & Derivatives
    Behçet syndrome: a contemporary view. (2018)
    Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. (2019)

  2. Saadoun, David   Google Publications
    Service de Médecine Interne, Centre Hospitalier Universitaire La Pitié Salpêtrière, AP-HP, Paris, France.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Immunosuppressive Agents; Nervous System Diseases; Venous Thrombosis; Aneurysm; Eye Diseases
    Categories: Drug Therapy; Therapeutic Use; Complications; Etiology; Immunology; Epidemiology
    2018 update of the EULAR recommendations for the management of Behçet's syndrome. (2018)
    Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. (2015)

  3. Tugal-Tutkun, Ilknur   Google Publications
    Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University , Istanbul, Turkey.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Uveitis; Immunosuppressive Agents; Antibodies, Monoclonal, Humanized; Genetic Predisposition to Disease; Interferon-alpha
    Categories: Drug Therapy; Genetics; Therapeutic Use; Diagnosis; Immunology; Pathology
    2018 update of the EULAR recommendations for the management of Behçet's syndrome. (2018)
    Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. (2010)

  4. Hatemi, Gulen     ClinicalTrials.gov Google Publications
    Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey .
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Immunosuppressive Agents; Gastrointestinal Diseases; Antirheumatic Agents; Biological Products; Infliximab
    Categories: Drug Therapy; Therapeutic Use; Complications; Diagnosis; Epidemiology; Etiology
    2018 update of the EULAR recommendations for the management of Behçet's syndrome. (2018)
    Behçet syndrome: a contemporary view. (2018)

  5. Yazici, Hasan   ClinicalTrials.gov Google Publications
    Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Review 
    Subjects: Immunosuppressive Agents; Pulmonary Artery; Venous Thrombosis; Aneurysm; Familial Mediterranean Fever
    Categories: Drug Therapy; Complications; Etiology; Therapeutic Use; Epidemiology; Genetics
    2018 update of the EULAR recommendations for the management of Behçet's syndrome. (2018)
    Behçet syndrome: a contemporary view. (2018)

  6. Rosenbaum, James T   Rheumatology   Google Publications
    Departments of Ophthalmology and Medicine, Division of Rheumatology, Oregon Health & Science University, Portland, Oregon; Department of Ophthalmology, Legacy Devers Eye Institute, Portland, Oregon. Top Hospital
    Physician  Guideline  Review 
    Relevant US NIH Grant Funding: $1,155,000 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 78/100
    Disclosed payments in 2021 from 10 biomedical companies, totalling $21,633.63, including $10,221.75 from  Novartis Pharma AG
    Subjects: Uveitis; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asians
    Categories: Therapeutic Use; Genetics; Drug Therapy; Immunology; Antagonists & Inhibitors; Diagnosis
    Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. (2014)
    Identification of a susceptibility locus in STAT4 for Behçet's disease in Han Chinese in a genome-wide association study. (2012)

  7. Emmi, Giacomo   Google Publications
    Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Uveitis; Antirheumatic Agents; Interleukin 1 Receptor Antagonist Protein; Adalimumab; Thrombosis
    Categories: Drug Therapy; Therapeutic Use; Complications; Administration & Dosage; Metabolism; Etiology
    Vascular Behçet's syndrome: an update. (2019)
    Behçet's syndrome patients exhibit specific microbiome signature. (2015)

  8. Cantarini, Luca   Google Publications
    Research Centre of Systemic Autoinflammatory Diseases, Behçets Disease Clinic and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Department of Medical Sciences, Surgery and Neurosciences, University of Siena , Siena, Italy.
    Scientist  Highly Cited  Highly Published  Case Reports  Review 
    Subjects: Uveitis; Antirheumatic Agents; Interleukin 1 Receptor Antagonist Protein; Antibodies, Monoclonal; Adalimumab
    Categories: Drug Therapy; Therapeutic Use; Administration & Dosage; Complications; Antagonists & Inhibitors; Blood
    Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. (2016)
    Anakinra treatment in drug-resistant Behcet's disease: a case series. (2015)

  9. Seyahi, Emire   Google Publications
    Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, 81310, Turkey. .
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Venous Thrombosis; Familial Mediterranean Fever; Pulmonary Artery; Aneurysm; Genetic Predisposition to Disease
    Categories: Genetics; Complications; Drug Therapy; Etiology; Therapeutic Use; Epidemiology
    Behçet syndrome: a contemporary view. (2018)
    Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. (2013)

  10. Jabs, Douglas A   Ophthalmology  Google Publications
    Departments of Ophthalmology and Medicine, the Mount Sinai Medical School, New York, New York; Department of Epidemiology, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. Top Hospital
    Physician  Guideline  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Subjects: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Immunosuppressive Agents; Scleritis
    Categories: Therapeutic Use; Drug Therapy; Antagonists & Inhibitors; Diagnosis; Physiopathology
    Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. (2014)
    Factors predictive of remission of new-onset anterior uveitis. (2014)

  11. Read, Russell W   Ophthalmology  Google Publications
    Department of Ophthalmology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama. Top Hospital
    Physician  Guideline  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 75/100
    Disclosed payments in 2021 from 2 biomedical companies, totalling $105.19, including $105.19 from  Johnson & Johnson Surgical Vision, Inc.
    Subjects: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Immunosuppressive Agents; Scleritis
    Categories: Therapeutic Use; Drug Therapy; Antagonists & Inhibitors
    Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. (2014)
    Author reply: To PMID 24359625. (2014)

  12. Gül, Ahmet   ClinicalTrials.gov Google Publications
    Department of Internal Medicine, Division of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Review 
    Subjects: Genetic Predisposition to Disease; Antibodies, Monoclonal, Humanized; Genome-Wide Association Study; HLA-B51 Antigen; Immunosuppressive Agents
    Categories: Genetics; Immunology; Diagnosis; Drug Therapy; Therapeutic Use; Adverse Effects
    Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. (2010)
    Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. (2013)

  13. Nowatzky, Johannes   Rheumatology  Google Publications
    Internal Medicine, Division of Rheumatology, New York University, New York City, New York, USA.
    Physician  Case Reports 
    Relevant US NIH Grant Funding: $834,788 over the last 5 years
    Medicare MIPS (Merit-based Incentive Payment System) rating: 86/100
    Subjects: Venous Thrombosis; Anticoagulants; Arteritis; Arthritis, Rheumatoid; Astrocytoma
    Categories: Diagnosis; Drug Therapy; Etiology; Administration & Dosage
    Major vessel thrombosis in Behçet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. (2012)
    Headaches related to rheumatologic disease. (2013)

  14. Papaliodis, George N   Ophthalmology  Google Publications
    Harvard Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA, 02114, USA.
    Physician  Case Reports 
    Medical school: University of Texas Southwestern Medical School at Dallas (MD, 1995)
    Medicare Accepted
    Subjects: Biological Products; Deglutition Disorders; Fever; Headache; Hypesthesia
    Categories: Diagnosis; Drug Therapy; Pathology; Complications; Etiology; Methods
    The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. (2011)
    Pre-papillary vitreous opacities associated with Behçet's disease: a case series and review of the literature. (2017)

  15. Calamia, Kenneth T   Rheumatology   Google Publications
    Mayo Clinic College of Medicine, Jacksonville, FL 32225, USA.  Top Hospital
    Physician  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 70/100
    Disclosed payments in 2021 from 8 biomedical companies, totalling $732.7, including $211 from  Genentech, Inc.
    Subjects: Oral Ulcer; Phosphodiesterase 4 Inhibitors; Thalidomide
    Categories: Drug Therapy; Analogs & Derivatives; Pathology; Therapeutic Use
    Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. (2015)
    Major vessel involvement in Behçet's disease: an update. (2011)

  16. Yang, Peizeng   Google Publications
    The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, Chongqing, PR China. Electronic address: .
    Scientist  Highly Cited  Highly Published  Clinical Trial 
    Subjects: Polymorphism, Single Nucleotide; Uveomeningoencephalitic Syndrome; Asians; Genetic Predisposition to Disease; Ethnicity
    Categories: Genetics; Metabolism; Immunology; Ethnology; Pharmacology; Physiology
    A metagenomic study of the gut microbiome in Behcet's disease. (2018)
    No association of PTPN22 polymorphisms with susceptibility to ocular Behcet's disease in two Chinese Han populations. (2012)

  17. Mahr, Alfred  Google Publications
    Department of Internal Medicine, Hospital Saint-Louis, Paris, France.
    Scientist  Highly Cited  Highly Published  Guideline  Clinical Trial  Review 
    Subjects: Immunosuppressive Agents; Oral Ulcer; Outcome Assessment, Health Care; Spondylarthritis; Anti-Inflammatory Agents, Non-Steroidal
    Categories: Drug Therapy; Genetics; Complications; Diagnosis; Therapeutic Use; Epidemiology
    2018 update of the EULAR recommendations for the management of Behçet's syndrome. (2018)
    Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. (2019)

  18. Takeno, Mitsuhiro  Google Publications
    Department of Allergy and Rheumatology, Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Intestinal Diseases; Gastrointestinal Diseases; HLA-B51 Antigen; Nervous System Diseases; Thalidomide
    Categories: Genetics; Therapeutic Use; Drug Therapy; Epidemiology; Pathology; Physiopathology
    Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. (2013)
    Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. (2010)

  19. Ishigatsubo, Yoshiaki  ClinicalTrials.gov Google Publications
    Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Nervous System Diseases; Adrenal Cortex Hormones; Brain; Gastrointestinal Diseases; Genetic Predisposition to Disease
    Categories: Genetics; Therapeutic Use; Drug Therapy; Pathology; Epidemiology; Physiopathology
    Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. (2013)
    Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. (2010)

  20. Cacoub, Patrice  Google Publications
    Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et Immunologie Clinique, Paris, France.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Immunosuppressive Agents; Nervous System Diseases; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal
    Categories: Therapeutic Use; Drug Therapy; Complications; Etiology; Immunology; Administration & Dosage
    Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. (2015)
    Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. (2012)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);